Japanese generics maker eyes Kyorin buyout

Sawai Pharmaceutical (4555.T), one of Japan's top makers of generic drugs, has bought almost five percent of Kyorin (4569.T) and wants to turn the mid-sized drugmaker into a wholly owned unit through a tender offer, the Nikkei reported. Report

Suggested Articles

GlaxoSmithKline GSK House in Brentford, UK
Manufacturing

GSK signs $231M Samsung deal to expand biologics manufacturing

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

by Angus Liu
Amarin Vascepa box
Pharma

Amarin's Vascepa loses another shield with Hikma's generic OK

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

by Eric Sagonowsky
yellow traffic light
Pharma

Twice-delayed Intercept NASH application faces another setback

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting. 

by Eric Sagonowsky